Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab proof-of-concept study in adults with cholinergic urticaria resistant to H1-antihistamines
2017-001262-25Phase 2Completed
- Sponsor
- Charité – Universitätsmedizin Berlin
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Cholinergic Urticaria (CU) comparing Dupixent with Placebo (2 arms). Started Aug 2018; status: completed.
02
Drugs
03
Conditions
Cholinergic Urticaria (CU)
Beyond the preview
Go deeper on 2017-001262-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001262-25.